SOST and chronic kidney disease: A positive association between high serum levels of sclerostin and FGF23 has also been found in chronic kidney disease and other bone diseases related to alteration in mineral metabolism [28,70]; on the other hand, low levels of sclerostin are linked with decreased FGF23 levels, overgrowth, and sclerosis of the skeleton [69].